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ABSTRACT (298/300 words) 
 
The prognostic importance of lymph node status and tumour infiltrating 
lymphocytes (TILs), is well established, particularly TILs in triple negative 
breast cancers (TNBCs). So far, few studies have interrogated changes in 
involved and uninvolved lymph nodes (LNs) and evaluated if their 
morphological patterns add valuable information for the prediction of disease 
progression in breast cancer. 
 
In a cohort of 309 patients enriched for TNBCs (170/309), we histologically 
characterised immune and stromal features in primary tumours and 
associated involved and uninvolved axillary LNs on routine haematoxylin and 
eosin stained sections. Out of the 309 patients, 143 had LN-positive disease. 
Twenty-five histopathological features were assessed, including the degree of 
TIL presence, quantitative and qualitative assessment of germinal centres 
(GCs) and sinus histiocytosis. Multivariate and cross-validated proportional 
hazard regression analyses were used to identify optimal covariate sets for 
prediction of distant metastasis free survival (DMFS). 
 
The degree of intratumoural and peritumoural immune infiltrate was 
associated with architectural changes in both uninvolved and involved LNs. 
By including clinicopathological characteristics as well as tumour and LN 
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histopathological features in L2-regularised proportional hazard models, the 
prediction of 5-year DMFS was improved by 3-15% over the baseline in all 
cancers and in TNBCs. In LN-positive cancers, the combination of Salgado’s 
classification, lymphocytic lobulitis, size and number of GCs in the uninvolved 
LN and location of GCs in the involved LN carried significant prognostic 
information. From these features, a multivariate cross-validation-stable risk 
signature was constructed, which identified low-risk groups within both LN-
positive breast cancers and the LN-positive TNBCs group with a 10-year 
DMFS probability of 78% and 87%, respectively. 
 
This study illustrates that by incorporating histopathological patterns of 
involved and uninvolved LNs combined with immune and stromal features of 
primary tumour, the prediction of developing distant metastasis in LN-positive 
breast cancers can be estimated more accurately. 
 
 
Keywords: (3-10) immune and stromal tumour-environment, multivariate 
distant metastasis free survival analysis, lymph nodes, triple negative breast 
cancers, lymph node positive breast cancer. 
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INTRODUCTION  
 
In invasive breast cancer, tumour size and the number of involved lymph 
nodes (LNs) have an inverse linear relationship with prognosis [1] and guide 
clinical decisions. Historical ten-year survival after local therapy alone 
(surgery and radiotherapy) in patients with node negative disease is ~85%, 
whilst for patients with involved axillary LNs it is 40-50% [2]. Emerging data 
has identified patients with a low risk for recurrence amongst LN-positive 
breast cancers who may be spared aggressive treatments. LNs are classified 
as involved with metastasis by pathological examination of conventional 
haematoxylin and eosin (H&E) sections, depending on the number of 
cancerous cells and size of the largest malignant deposit [3]. However, 
controversy regarding thresholds for these variables in addition to results from 
recent clinical trials in which occult metastasis were retrospectively evaluated 
[4], illustrate the uncertainty around the prognostic LN features on disease 
recurrence.  
 
Accumulating evidence supports the prognostic and predictive role of the host 
immune response in early stage breast cancers, especially in oestrogen 
receptor (ER)-negative, progesterone receptor (PR)-negative and HER2-
negative (i.e. triple negative) breast cancers (TNBCs) [5-7]. Recent studies 
have shown that stromal tumour infiltrating lymphocytes (TILs), as opposed to 
intratumoural TILs, are potentially useful biomarkers in predicting response to 
therapy and overall outcome, when assessed via light microscopy of H&E-
stained tissue [5,8,9]. Most studies to date have focused on the assessment 
of TILs within the primary tumour whilst largely ignoring peritumoural and 
nodal patterns of immune infiltrates. Clinical relevance of cell type specific 
alteration in LNs was provided by Khort et al., who demonstrated that the 
number of CD4 T cells and CD1a dendritic cells in axillary LNs allowed a 
more significant stratification of disease-free survival for 77 breast cancer 
patients with small and medium-sized tumours than all other clinico-
pathological features [10]. 
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The aim of this study was (i) to comprehensively catalogue the 
histopathological features of immune cell and other mesenchymal stromal 
infiltrates within tumour tissue, peritumoural tissue and axillary nodal tissue 
and (ii) to determine whether any of these features are of prognostic value in 
breast cancer. Given the large number of features evaluated in relation to the 
small-sized patient cohorts, we implemented an L2-regularised multivariate 
Cox proportional hazard model with repeated cross-validation to identify 
robust and generalisable putative predictors of developing distant metastasis. 
 
 
MATERIALS AND METHODS 
 
Study design and patients 
This is a retrospective study of patients with invasive breast carcinoma treated 
between 1984 to 2002 at Guy’s Hospital London, UK. Ethical clearance was 
obtained from the local research ethics committee. H&E stained sections of 
formalin fixed paraffin embedded (FFPE) tissue from primary invasive breast 
carcinomas, along with their involved and uninvolved LNs, were retrieved from 
the King’s Health Partner’s Breast Cancer Tissue and Data Bank (London, 
UK) from 309 patients. The cohort was enriched for TNBCs patients with an N 
of 170 (142 of which were described previously [11]), whilst 139 patients had 
non-TNBC (hormone receptor-positive/HER2-negative (N=62), hormone 
receptor-negative/HER2-positive (N=59) and hormone receptor-
positive/HER2-positive (N=18)). LN status was available for 276/309 patients. 
143 (52%) patients were LN-positive whilst 133 (48%) had LN-negative 
disease. Uninvolved axillary LNs were available for 134/143 patients with LN-
positive disease. In the remaining nine LN-positive patients, all harvested 
nodes were involved. Clinicopathological data for each patient, including age 
at diagnosis, baseline tumour characteristics such as invasive size, 
histological grade, histological subtype, ER, PR and HER2 status, and 
immunohistochemistry (IHC)) for cytokeratins (CK) 5 and 14 and epidermal 
growth factor receptors (EGFR) status, LN involvement and distant 
metastases were recorded (Table 1) and some have previously been 
described [11]. 
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Histopathological immune assessment: 
 
Classification of immune infiltrates 
All routine H&E stained sections of primary breast tumours and uninvolved 
and involved LNs were reassessed histopathologically. A minimum of 6 
sections of the primary tumour and 1-12 (mean=6) LNs per case were 
available for evaluation of immune and stromal features. All sections were 
reviewed by a specialist Consultant Breast Pathologist (SEP) and Pathology 
Research Scientist (PG). Analyses of the tumour microenvironment were 
performed using conventional microscopy of H&E whole sections. The 
NanoZoomer HT Digital Pathology Scanning System (Hamamatsu, Japan), 
was used to scan H&E sections with a spatial resolution of 0.46 μm/pixel for 
the measurement of LN germinal centres (GCs). According to 
recommendations by the International Tumour Infiltrating Lymphocytes 
Working Group [12], morphological features initially assessed as continuous 
variables (e.g. stromal TILs) were discretised for statistical analysis. All 
features and their associated categories described below in detail are 
summarised in Supplementary Table S1A & S1B. 
 
Intratumoural site: 
Immune infiltrates were assessed semi-quantitatively across the entire tumour 
section and then in different tumour regions. As per Salgado’s criteria, TILs 
were classified as ‘stromal TILs’ (Figure 1A-C) or ‘intratumoural TILs’ (Figure 
1D). Stromal TILs were further subclassified as TILs scattered within the 
tumour stroma (Figure 1A); TILs around tumour cell nests (Figure 1B) and 
TILs seen at the invasive margin (Figure 1C). The degree of TILs present was 
further graded semi-quantitatively as: 0=absence of lymphocytes, 1=minimal 
(1 - 10% of surface area in a given location); 2=mild (10 - 20%); 3=moderate 
(>20 - 50%); and 4=strong (≥50%). 
 
Peritumoural site (including premalignant and non-tumorous 
components): 
Immune infiltrates in situ and normal tissue adjacent to invasive tumours were 
assessed when seen (i) next to DCIS (Figure 1E), (ii) in normal breast lobules 
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(Figure 1F), and (iii) in perivascular areas (Figure 1G). Lymphocytic lobulitis 
([13](Figure 1H) and tertiary lymphoid structures (TLS) were graded as 
present or absent (Figure 1I). 
 
Stromal features:  
Assessment of stromal features in the invasive tumours was based on their 
overall appearances and recorded as oedematous/myxoid (Figure 1J), 
hyalinised (Figure 1K) and/or fibroblastic (Figure 1L); when a mixed pattern 
was present, the predominant feature was recorded. Smooth muscle actin 
(SMA) and alcian blue staining of selected cases supported the H&E stromal 
classification (Supplementary Figure S1). 
 
Involved and uninvolved axillary LNs 
Three main morphological immune features were assessed in axillary 
involved LNs: A) Germinal centre features, B) Degree of sinus histiocytosis 
and C) Pattern of metastatic tumour involvement (Supplementary Table S1B). 
In uninvolved LN, only A) and B) were assessed: 
 
(i) The number of GCs was categorised as grade 0 (absent), 1 (few), 2 
(moderate) or 3 (numerous, frequently distributed throughout the LN) (Figure 
2 A). (ii) The distribution of GCs was classified as predominantly peripheral 
(majority close to the capsule), predominantly central (most GCs in the centre 
of the LN) (Figure 2A) or mixed architecture (GCs were located across the 
whole LN). (iii) Average size of GCs was classified as either small (< 200 µm 
in diameter), moderate (200-400 µm), large (> 400 µm) or mixed (if more than 
one size) (Figure 2B). In those with mixed sizes of GCs, cases with a 
predominant pattern of large GCs, were further classified as “GC hyperplasia”. 
Supplementary Figure S2 shows staining CD20 (B cell marker) and CD11c 
(dendritic cell marker) on selected cases, which corroborated the classification 
of morphological changes in the germinal centres of the LNs. 
 
Sinus histiocytosis was assessed using a modification of the method 
previously described by Culter et al. [14]. The number of histiocytes across 
the sinuses was classified as: grade 0 (absent), grade 1 (<2 cells), grade 2 (2-
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4 cells), grade 3 (>4-<8 cells) or grade 4 (≥8 cells across the sinus) (Figure 
2C). The dilatation of sinuses by cells other than histiocytes, for example by 
metastatic tumour cells, or other inflammatory cells or oedema fluid, was 
ignored. 
 
The metastatic tumour spread within the LN was classified into six patterns: i) 
sub-capsular (within the sinus immediately under the LN capsule) (Figure 2D), 
ii) intra-sinusoidal (within sinuses in the body of the LN (Figure 2E), iii) diffuse 
(Figure 2F), iv) nodular (Figure 2G), v) mixed (mixture of several patterns) and 
vi) total replacement by tumour. 
 
Data analysis and interpretation 
The end point of the study was distant metastasis free survival (DMFS), which 
was calculated from the date of diagnosis of the primary tumour to the first 
event of any distant metastases. An L2-regularised multivariate proportional 
hazard model, based on iterative determination of optimal covariates to 
prevent overfitting via repeated cross-validation, was applied to all breast 
cancers (N=309), TNBC (N=170) patients, and their LN-status dichotomised 
subgroups [15-18]. Three sets of covariates were used in the analytical 
models: group A included 8 clinico-pathological features, group B 
encompassed histologically assessed immune and stromal features and group 
C was a combination of A and B. Figure 3 provides a CONSORT diagram 
explaining cohorts used for statistical analyses. A detailed description of the 
statistical analysis is provided in Supplementary Method and Supplementary 
Figure S3. In brief, each analysis was performed with 100 iterations and their 
results were averaged. The fraction of correctly predicted patients was 
recorded after 1 year, and every year up to 10 years of DMFS. At each time 
point, an optimal set of covariates with the highest prediction accuracy was 
determined by ranking the covariates according to their relevance in the cross-
validated Cox regression analysis. Regression parameters for each covariate 
were reported as hazard ratios (HR) with 95% confidence intervals (CI) [19].  
For LN-positive cohorts, an optimal covariate-set to predict 5-year DMFS was 
established to construct a single-patient immune and stromal histopathological 
(ISH)-risk score, by summing the standardised covariates weighted by their 
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coefficients. LN-positive patients were grouped into those with low and upper 
quartile, and mean risk signature scores. Kaplan Meier estimators were used, 
and the log-rank test was performed to test differences among groups.  
 
 
RESULTS 
 
Clinicopathological characteristics of the patients 
The clinicopathological features of the 309 evaluated patients are 
presented in Table 1. First analysis was restricted to TNBC patients 
(N=170, 81 with LN-negative and 64 with LN-positive disease and 25 
patients within unknown LN-status), followed by randomly selected non-
TNBC patients (N=139; 52 with LN-negative, 79 LN-positive and 8 with 
unknown LN status). All patients were female with a median age of 55 
years (range=24-89) at diagnosis. Most (N=183; 59%) patients had T2 
tumour size and a predominant number of cases (N=253; 82%) were 
histologically grade 3, as might be expected in a cohort enriched for TNBC 
and for LN positive cases. Most cases were invasive breast carcinomas of 
no special type (82%). Lymphovascular invasion (LVI) was seen in 90 
(29%) cases. Median follow-up was 7.9 years for the entire cohort 
(range=0.3-25). Distant metastasis was recorded in 129 (42%) patients, of 
whom 70% developed distant metastasis within the first 2.5 years after 
diagnosis (range of DMFS 0.3-18 years). 
 
Lymphocytic infiltration at invasive and peritumoural sites 
 
Intratumoural sites: 
An absence of lymphocytic infiltration across the entire tumour was noted in 6 
(3.5%) TNBC patients compared with 18 (12.9%) non-TNBC patients. The 
majority of TNBC patients had a moderate (N=78, 45.9%) or strong (N=23, 
13.5%) degree of lymphocytic infiltration across the entire tumour. In contrast, 
a majority of non-TNBC patients had minimal (N=45, 32.4%) or mild (N=36, 
25.9%) degree of infiltration. A strong degree of lymphocytic infiltration across 
the entire tumour was seen only in 5 (3.6%) non-TNBC patients. Intratumoral 
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TILs were present in more TNBC patients (N=51, 30%) compared with non-
TNBC patients (N=10, 7.2%). Likewise, a strong degree of TILs at the 
invasive margins was noted in more TNBC (N=22, 12.9%) than non-TNBC 
patients (N=2, 1.4%). 
 
Peritumoural sites 
In 130 of the total 309 cases, DCIS was seen in close proximity to the 
invasive tumour. In 48/130 (36.9%) cases, the DCIS was free of lymphoid 
infiltrate, whilst the rest had varying degrees of immune infiltrates. A strong 
lymphoid infiltrate was found surrounding breast lobules in the TNBC group 
(N=40, 30.5%) compared with the non-TNBC group (N=20, 17.5%). 
Lymphocytic lobulitis and TLS in areas surrounding the invasive tumours were 
seen more frequently in TNBC cases (16% and 27.6%, respectively) 
compared with non-TNBCs, (9.6% and 17.3%, respectively). 
 
Tumour stroma  
Fibroblastic stroma was the most common intratumoural stromal change 
noted accounting for 87% cases, followed by hyalinised stroma in 86% cases 
and myxoid change was the least common noted in 23% cases. No 
differences were noted across tumour subgroups (Table 2B). 
 
Histological evaluation of involved and uninvolved axillary lymph nodes  
Primary tumours may lead to reactive and structural changes in regional 
lymph nodes prior to development of nodal metastases [20,21]. A total of 
267 uninvolved and 143 involved lymph nodes were reviewed. GCs were 
present in 193 uninvolved lymph nodes (72%), and 97 involved lymph 
nodes (67%) and assessed for their number, location and size. Within 
involved lymph nodes, GCs were located mainly in the periphery (52.6%) or 
predominantly in the centre of LNs (21.6%) (Table 2C). The numbers of 
large GCs, and the overall size distribution in uninvolved and involved LN 
was comparable (Table 2C). Similarly, the frequency of grade 3-4 sinus 
histiocytosis was comparable. 
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Correlation of histopathological features of intratumoural, 
peritumoural, stromal and nodal sites 
We next investigated whether the degree and presence of these 
histological features occurred independently. Using a Pearson’s correlation, 
there was a concurrent increase in the degree of lymphocytic infiltrate at the 
invasive tumour, around tumour nests, at the peripheral tumour edge and 
within the stroma (Supplementary Figure S4). We also noticed that in all 
breast cancers and particularly among TNBCs, the number and size of the 
GCs in uninvolved and involved lymph nodes grew with increasing levels of 
immune infiltrates at the primary tumour site (r: 0.46, P <0.001; 
Supplementary Figure S4). 
 
Immune-associated characteristics improve prognostic accuracy of 
DMFS 
Next, we asked whether these novel histomorphological features carry 
prognostic information for the development of distant metastases. Given 
that several of these immune and stroma cell patterns do not occur 
independently (Supplementary Figure S4), we used a Bayesian multivariate 
survival analysis algorithm optimised to undo the possible effects of 
overfitting [18]. We analysed three groups of covariates (A, B, C) first in all 
breast cancers and then in the TNBC cohort only. We then evaluated their 
performance in correctly predicting the fraction of patients free of distant 
metastasis at 5 years after diagnosis in comparison to the baseline 
performance in which no covariates were used and in which the risk of 
distant metastasis is derived solely on any imbalance between cases and 
controls (Figure 4, vertical grey line). Covariate-group A included 8 
clinicopathological features; ER, PR and HER2 status, histological grade, 
lymph node status, tumour size, age at diagnosis and the presence or 
absence of LVI. Group B encompassed the 25 histologically assessed 
features described above in detail (14 features are from the primary tumour 
site and 11 features were obtained from involved and uninvolved LNs, 
Supplementary Table 1). In group C, we combined groups A and B. In all 
breast cancers, covariate-group A correctly predicted 5-year DMFS in 68% 
of patients (green lines, Figure 4A). This was a modest improvement 
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compared to 62% baseline performance (dotted line, Figure 4A) and the 
covariate-group B (red line, Figure 4A). The combined covariate-group C 
performed best by correctly predicting 5-year DMFS in 71% of patients 
(black line, Figure 4A). In TNBC, the differences in predictive accuracy 
between groups A, B and C were less pronounced. Of note, within the 
TNBC cohort, covariate-group B (red line, Figure 4B) was more accurate in 
predicting 5-year DMFS (71%) than either group A (67%, green line, Figure 
4B) or the baseline performance (67%, dotted line, Figure 4B). The optimal 
covariates among the covariate-group B were selected as being risk-
predictive at 5-year DMFS, namely TILs in the primary tumour according to 
Salgado’s criteria [12], the number and size of GCs in the uninvolved LN, 
the location of GCs and a diffuse metastatic pattern in the involved LN, as 
well as the presence of lymphocytic lobulitis in adjacent normal breast 
tissue (Table 3). Supplementary Table 2A provides the full list of optimal 
covariates selected at 5-year DMFS in both cohorts for each of the three 
covariate-groups used in these analyses. 
 
A risk score based on histomorphological features identifies LN-
positive breast cancers patients with low risk for distant metastasis 
Since morphological patterns in involved and uninvolved LNs carried 
prognostic value, we asked if these features were predictive for developing 
distant metastasis in both LN-positive and LN-negative disease. All breast 
cancers and TNBCs group were further divided into patients with LN-
positive (143 all cancers and 64 TNBC), and LN-negative disease (133 all 
cancers and 81 TNBC). These four sub-cohorts were then analysed 
independently with L2-regularised proportional hazards models using 
covariate-group B. In the LN-positive cohorts, covariates were selected via 
cross-validation for predicting a 5-year DMFS, including Salgado’s 
classification, the presence of lymphocytic lobulitis, the size and number of 
GCs in the uninvolved LN and location of GCs in the involved LN (Table 3, 
Supplementary Table 2B and 2C). Incorporating these five features 
improved the 5-year DMFS predictive accuracy from 50% baseline 
performance (dotted line, Figure 4C) to 64% in all breast cancers (red line, 
Figure 4C) and from 58% baseline performance (dotted line, Figure 4D) to 
Prognostic value of histological immune and stromal features	
	 13 
73% in TNBC (red line, Figure 4D). Amongst the two LN-negative cohorts, 
covariate-group B failed to improve 5-year DMFS predictive accuracy 
(Supplementary Figure S5). Due to the smaller datasets in these sub-
cohorts, residual overfitting cannot be excluded.  
 
Lastly, we built an “immune-stroma-histological (ISH)-risk score” with these 
5 histomorphological features (see Supplementary Method), and grouped 
patients according to their ISH-risk score levels. Patients with the lowest 
quartile ISH-risk scores had a 10-year DMFS of 78% (all breast cancer 
cohort) and 87% (TNBC cohort) compared with 17% (all breast cancer 
cohort) and 18% (TNBC cohort) for patients with an upper quartile ISH-risk 
score (Kaplan Meier survival estimates; log-rank test of difference in 
survival, p < 0.001, HR = 5.15, 95% CI 3.8–6.97; p < 0.001, HR = 14.26, 
95% CI 7.48–27.19) (Figure 4E & F). Moreover, LN-positive breast cancer 
patients with low ISH-risk score had even less risk of developing distant 
metastases than LN-negative breast cancer patients (Figure 4E & F, black 
dotted line). This suggests that histomorphological changes within 
uninvolved and involved LN carry significant prognostic information for the 
risk of distant metastasis amongst LN-positive patients, even among triple 
negative breast cancers. 
 
 
DISCUSSION 
 
It is well known that routinely assessable clinicopathological characteristics 
such as LN status or the presence of TILs predict the risk of recurrence, 
distant metastases and overall outcome in breast cancer patients. In this 
study, we have utilised an optimised multivariate proportional hazard model 
for analysing ‘time-to-event’ data which was based on extensive H&E 
histopathological data to determine whether these features are of 
prognostic value in breast cancer. Reassuringly, well-established 
prognostic markers were shown to be associated with outcome, including 
the presence of LN metastases whilst we also confirm the value of the 
Salgado classification [12]. We report, for the first time, that the number and 
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architecture of GCs in involved and uninvolved LNs, as well as the 
presence of lymphocytic lobulitis, provide important information for outcome 
prediction. Selected through L2-regularised and cross-validated 
proportional hazards models, we have developed a novel risk score, 
identifying patients with low risk for developing metastases even amongst 
patients with LN-positive breast cancers. 
 
There is now increasing interest in the role of the tumour microenvironment 
in cancer prognosis and, in particular, the role of lymphocytic infiltrates and 
stromal reactions. TIL composition within the primary invasive tumour has 
proven to be superior to the classical TNM staging in predicting outcome in 
some series [12]. TIL composition has also been shown to be predictive of 
response to chemotherapeutic agents [8,20-22]. Much of this, however, 
relies on complex multi-parametric surface phenotyping of TILs from fresh 
frozen or freshly dissociated tissues. Unsurprisingly, given the technical 
challenges, financial constraints and operator dependence, these immune 
scoring systems have not been widely adopted in routine clinical practice 
despite their potential benefits. Our work provides a novel scoring system 
that can accurately predict DMFS, particularly in LN-positive and triple 
negative breast cancers, based on routine H&E histopathological 
examination. Hence, unlike complex multi-parametric assays, our method 
could be easily integrated into standard clinical practice. 
 
To our knowledge, we are the first to include the histological features of 
uninvolved LNs into a predictive model of DMFS for breast cancer patients. 
Although draining LNs are the first site of metastasis for many cancers, the 
histological progression from an uninvolved to an involved LN remains 
poorly documented. A recent study in murine models found that the stromal 
compartments in uninvolved LNs undergo structural reorganisation due to 
the proliferation and transcriptional changes of fibroblastic reticular cells, 
potentially providing a pro-tumour environment [22]. While we cannot 
attribute changes to specific cell types within the uninvolved LNs, we 
observed in this study that patients with shorter time to any distant 
metastasis had fewer and larger GCs, which were predominantly located in 
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the centre of the node. GCs are dynamic structures where B cells 
expressing high-affinity, potentially tumour-reactive antibodies mature into 
antibody-secreting plasma cells and memory B cells. Further studies are 
clearly warranted to elucidate molecular signals in uninvolved LNs that may 
predict development of nodal metastases. 
 
The presence of lymphocytic lobulitis adjacent to the primary tumour was 
another feature associated with a reduced risk of recurrence in all breast 
cancers and TNBCs, including LN-positive cohorts. Lymphocytic lobulitis is 
characterised by perilobular and perivascular aggregates of B and T 
lymphocytes with increased expression of MHC class II antigens by the 
lobular and ductal epithelium and has been described in prophylactic 
mastectomies from women with BRCA1/2 mutations [23]. In normal breast 
tissue, immune cells are predominantly localised to lobules. In lymphocytic 
lobulitis, disproportionately higher numbers of T cells (CD4 and CD8) and B 
cells (CD20) are seen when compared with dendritic cells or 
monocytes/macrophages. The role of these cells in the breast is not entirely 
clear, although a role in tissue immune surveillance has been proposed 
[24]. 
 
Through incorporating the variability of immune and stromal composition at 
the primary tumour bed, along with architectural changes in uninvolved and 
involved LNs, we were able to develop an ISH-risk score to identify low-risk 
patients among LN-positive breast cancers. Effective biomarkers to guide 
clinical management is of particular importance in high-risk patients such as 
those with TNBC and LN-positive disease. These patients are often 
referred for adjuvant chemotherapy but only a proportion benefit from 
increased overall survival. Currently there is a lack of validated biomarkers 
to identify patients for whom less aggressive intervention might be 
appropriate. Our ISH-risk score was derived through an unbiased 
approach, in which we aimed to: (1) quantify the outcome prediction 
performance of regression results; (2) avoid overfitting via monitoring of 
outcome prediction on unseen data, and; (3) construct a multivariate risk 
signature based on the optimised covariate set. Thus, we propose that our 
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ISH-risk score might be used for effective patient stratification, although 
clearly this requires further evaluation.  
 
This study has several limitations. Firstly, the breast cancer cohort used 
was enriched for TNBCs (170/309) which frequently have increased 
immune infiltrates compared with other subtypes of breast cancer. Thus, 
future studies in cohorts with higher proportions of ER-positive or HER2-
positive breast cancers are warranted to corroborate the applicability of 
these histomorphological features. Secondly, as a high proportion of 
tumours, particularly TNBCs, were of histological grade 3, this pathological 
characteristic was non-discriminatory for risk prediction in this cohort. In 
cohorts with more typical distribution of histological grade of consecutive 
series of invasive breast cancers, the inclusion of histological grade in the 
multivariate model will need to be evaluated. Finally, we have not as yet 
sub-categorised immune and stromal cells in uninvolved LNs, particularly in 
the GCs, with orthogonal experiments such as IHC or immunofluorescence 
techniques. Although this would shed further light on the pro-tumour 
evolving microenvironment in these lymphoid organs, they are beyond the 
scope of this manuscript. 
 
In conclusion, our study highlights the added value of comprehensive 
histopathological examination of tumoural, peritumoural and nodal features 
for the prediction of distant metastases. By suppressing overfitting via 
repeated cross-validation and constructing reproducible multivariate risk 
signatures, our mathematical approach provides a robust method for 
survival analysis beyond the commonly used Kaplan Meier analyses. 
Furthermore, these results point towards a novel histopathological 
prognostic tool that improves 5-year DMFS prediction accuracy in high-risk 
breast cancers and if validated, could be implemented in standard 
histological practice. 
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TABLES 
 
Table 1. Clinicopathological features of all breast cancers and TNBC 
 
Table 2. A. Distribution of the immune features at tumoural and peri-tuoural 
sites assessed across TNBC and Non-TNBC subgroups. B. Distribution of the 
stromal features in TNBC and Non-TNBC subgroups. C: Pattern of 
histomorphological features in involved and uninvolved lymph nodes in LN-
positive and LN-negative patients. 
 
Table 3. Immune, stroma and lymph node feature selection from 
multivariate Bayesian Cox regression analyses. Features are listed and 
their hazard ratio shown if it was selected from group A (standard features), 
group B (immune & stroma features) and group C (all features). All cohorts 
that were used for analyses are reported. Covariates used for the Immuno- 
stroma -histological (ISH)-risk score are indicated in grey. 
 
 
  
Prognostic value of histological immune and stromal features	
	 22 
FIGURE LEGENDS 
 
Figure 1: Morphological assessment of the immune parameters in the 
intratumoural and peritumoural sites of the primary tumour. (H&E stain). 
(I) Intratumoural site:  
(A) TILs scattered in the intratumoural stroma (score 4; ≥50%; strong); (B) 
TILs around tumour cell nests, (score 4; ≥50%; strong); (C) TILs at the 
invasive tumour margin (score 4; ≥50%; strong); (D) Presence of 
intratumoural TILs (lymphocytes present within tumour cell nests ‘intra-
epithelial’).  
(II) Peritumoural components:  
(E) Lymphocytic infiltrate surrounding DCIS (score 3; ≥50%; strong); (F) 
Lymphocytic infiltrate surrounding normal breast lobules (score 3; ≥50%; 
strong); (G) Perivascular lymphocytic infiltrate (score 3; ≥50%; strong); (H) 
Presence of lymphocytic lobulitis (I) Presence of tertiary lymphoid structure 
(TLS) (lymphoid GC formation). Stromal features in the tumour environment: 
(J) oedematous/myxoid; (K) hyalinised stroma; (L) fibroblastic stroma. 
 
Figure 2: Histomorphological features of uninvolved and involved lymph 
nodes (H&E stain) 
In the uninvolved LNs: (A) numerous GCs (Grade 3) GC located throughout 
the LN (white arrows); (B) large GC (white arrow) with an adjacent small GC 
(black arrow); (C) sinus histiocytosis grade 4 (inset showing a higher power 
view). In the involved LNs: (D) supcapsular metastasis; (E) sinusoidal pattern 
(black arrows); (F) diffuse pattern (black arrows); (G) nodular pattern with 
near total replacement of the nodal tissue with metastatic deposits. 
 
Figure 3: Consort diagram of cohorts used in the optimised multivariate 
proportional hazard model. A) 309 breast cancer and 170 TNBC patients 
were analysed with group A (standard features, big dashed box); group B 
(immune & stroma features, small dashed box) and group C (combination of 
standard and immune & stroma, plus additional 8 characteristics, black box). 
B) Stratification of cohorts into LN-positive and LN-negative patients. 
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Multivariate proportional hazard model was applied using group B features 
(immune & stroma features, small dashed box). 
 
Figure 4: Optimised proportional hazards models to identify 
covariates for the prediction of developing distant metastasis in all 
invasive breast cancers and TNBC cohorts. Three different initial sets of 
covariates were used for the prediction analysis, namely 8 standard 
features (group A); 25 immune & stroma features (group B); and all 
available features in (group C). The dotted line in all graphs indicates the 
baseline performance without any covariates (i.e. based solely on any 
imbalance between cases and controls). The green, red and black, lines 
show the performance on the validation set including either group A, B and 
C, respectively. LN-positive patients of all breast cancers (C) and TNBC (D) 
were analysed with group B covariates. The LN-positive cohorts were 
further dichotomised based on the ISH-risk score. Kaplan Meier curves for 
all breast cancers (E) and TNBC (F) illustrating the duration of distant 
metastasis free survival (DMFS) according to lower quartile (green line), 
mean (blue line) and upper quartile (red line) of ISH-risk score grouping. 
Hazard ratio (HR), and confidence interval (CI) are listed below the graph. 
The black dotted lines display the survival curves for LN-negative patients 
of all breast cancers (N=133) and TNBC (N=81). 
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SUPPLEMENTARY DATA 
 
Supplementary Table 1: Histopathological evaluation of primary tumour 
microenvironment (14 characteristics), uninvolved lymph nodes (5 characteristics), 
and involved lymph nodes (6 characteristics). 
 
Supplementary Table 2: Results from multivariate L2-regularised and cross-
validated proportional hazard analysis using group A, B and C of immune and 
stroma histomorphologically assessed and clinicopathological characteristics. Taken 
at the 5 year prediction cut off time point. 
 
Supplementary Figure S1: Smooth muscle actin (SMA) and alcian blue staining 
of selected primary tumours with differing stromal features. 
 
Supplementary Figure S2: Germinal centres of the LNs stained with CD20 (B 
cell marker) and CD11c (dendritic cell marker). 
 
Supplementary Figure S3: Identification of overfitting point in the Bayesian batch 
Cox analysis. Graphs illustrating the fraction of correctly predicted disease 
outcome for patients (i.e. those who had an event prior the cut-off time) (prediction 
time point) over those patients who had either never distant metastasis or 
developed metastasis after this time point. The top and bottom lines represent the 
validation and test sets, respectively. The number of covariates used for the 
prediction is shown on the x-axis (nr of covs). Iteratively, covariates are removed 
from the analysis. 
 
Supplementary Figure S4: Correlations analysis of covariates. Plot showing all 
pairwise Pearson’s correlations for standard clinical features and all novel 
morphological assessed features across 309 breast carcinomas in (A) and for all 
histopathological characteristics across TNBC (B). The list of covariates is 
provided at the bottom, whereby immune-associated features are indicated in 
blue, features assessed in the uninvolved lymph node in purple, in the involved 
lymph node in green and standard clinic-pathological features in black. We also 
included the relevant outcome variable (TTE – time to event).  
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Supplementary Figure S5: Optimised proportional hazards models to identify 
covariates for the prediction of distant metastasis-free survival (DMFS) in all 
breast cancers LN-negative and TNBC LN-negative cohorts. 
 
Supplementary Materials and methods: Detailed description of the L2-regularised 
and cross-validated proportional hazard analysis. 
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Table  2
A Intratumoural and peritumoural assessment B Stromal features
Characteristics assessed TNBC Non-TNBC Characteristics assessed TNBC Non-TNBC 
N= 170 (%) N= 139 (%) P Value N= 170 (%) N= 139 (%) P Value
Semi-quantitative assessment of lymphocytic Oedemamtous/Myxoid stroma
infiltration across entire tumour   Absent 125 (73.5) 114 (82)
 Absence of lymphocytes 6 (3.5) 18 (12.9)  Present 41 (24.1) 25 (18) Fisher's exact-test
 Minimal (1-<10%) 18 (10.6) 45 (32.4) Dominant 4 (2.4) 0 (0) 6.79E-02
 Mild (10-20%) 45 (26.5) 36 (25.9)
 Moderate (>20-<50%) 78 (45.9) 35 (25.2) Chi-square-test Hyalinised stroma 
 Strong (≥50%) 23 (13.5) 5 (3.6) 6.94E-09   Absent 21 (12.4) 21 (15.1)
 Present 129 (75.9) 103 (74.1) Chi-square-test
TILs scattered in the intratumoural stroma Dominant 20 (11.8) 15 (10.8) 7.70E-01
 Absence of lymphocytes 14 (8.2) 32 (23)
 Minimal (1-<10%) 43 (25.3) 60 (43.2) Fibroblastic stroma 
 Mild (10-20%) 50 (29.4) 24 (17.3)   Absent 20 (11.8) 20 (14.4)
 Moderate (>20-<50%) 55 (32.4) 22 (15.8) Fisher's exact-test  Present 137 (80.6) 110 (79.1) Chi-square-test
 Strong (≥50%) 8 (4.7) 1 (0.7) 1.86E-07 Dominant 13 (7.6) 9 (6.5) 7.50E-01
TILs around tumour cell nests
 Absence of lymphocytes 41 (24.1) 61 (43.9)
 Minimal (1-<10%) 33 (19.4) 35 (25.2)
 Mild (10-20%) 29 (17.1) 14 (10.1) C Lymph node
 Moderate (>20-<50%) 55 (32.4) 24 (17.3) Chi-square-test LN-Negative Patients
 Strong (≥50%) 12 (7.1) 5 (3.6) 2.68E-04 Involved LN Uninvolved LN Uninvolved LN
N=143 (%) N=143 (%) N= 133 (%)
TILs at the invasive margin Germinal Centre (GC) assessable 97 (67.8) 88 (61.5) 105 (78.9)
 Absence of lymphocytes 12 (7.1) 40 (28.8) Complete absence of GC 26 (18.2) 46 (32.2) 28 (21.1)
 Minimal (1-<10%) 21 (12.4) 33 (23.7) Total metastatic replacement of LN 20 (14) NA NA
 Mild (10-20%) 44 (25.9) 33 (23.7) No uninvolved LN available for assessment NA 9 (6.3) NA
 Moderate (>20-<50%) 71 (41.8) 31 (22.3) Chi-square-test
 Strong (≥50%) 22 (12.9) 2 (1.4) 5.70E-10 GC semi-quantitative assessment
Grade 1 (Few) 37 (38.1) 34 (38.6) 45 (42.9)
Intratumoural TILs Grade 2 (Moderate) 41 (42.3) 31 (35.2) 29 (27.6)
  Absent 119 (70) 129 (92.8) Chi-square-test Grade 3 (Numerous) 19 (19.6) 23 (26.1) 31 (29.5)
 Present 51 (30) 10 (7.2) 1.14E-06
GC location
Lymphocytic infiltrate surrounding DCIS Peripheral 51 (52.6) 34 (38.6) 50 (47.6)
DCIS absent 108 (63.5) 71 (51.1) Predominantly peripheral 19 (19.6) 27 (30.7) 23 (21.9)
  Absent 21 (33.9) 27 (39.7) Central 6 (6.2) 0 (0) 0 (0)
 Mild (10-20%) 11 (17.7) 17 (25) Predominantly central 21 (21.6) 27 (30.7) 32 (30.5)
 Moderate (>20-<50%) 14 (22.6) 8 (11.8) Chi-square-test
 Strong (≥50%) 16 (25.8) 16 (23.5) 8.14E-02 GC size
Small 23 (23.7) 20 (22.7) 32 (30.5)
Salgado's classification Moderate 13 (13.4) 11 (12.5) 14 (13.3)
0-10% stromal TILs 39 (22.9) 77 (55.4) Large 4 (4.1) 4 (4.5) 4 (3.8)
20-40% stromal TILs 61 (35.9) 37 (26.6) Chi-square-test Mixed 57 (58.8) 53 (60.2) 55 (52.4)
50-90% stromal TILs 70 (41.2) 25 (17.9) 9.70E-09
GC hyperplasia
TILs surrounding normal breast lobules Absent 52 (53.6) 48 (54.5) 65 (61.9)
No normal breast lobules 39 (22.9) 25 (17.9) Present 45 (46.4) 40 (45.5) 40 (38.1)
Normal breast lobules Sinus histocytosis
Absent 26 (19.8) 35 (30.7) Grade 1 = <2 cells across 1 (1.1) 3 (2.2) 3 (2.3)
 Mild (10-20%) 30 (22.9) 34 (29.8) Grade 2 = 2 to 4 9 (9.5) 24 (17.9) 14 (10.5)
 Moderate (>20-<50%) 35 (26.7) 25 (21.9) Chi-square-test Grade 3 = >4 to <8 41 (43.2) 50 (37.3) 61 (45.9)
 Strong (≥50%) 40 (30.5) 20 (17.5) 3.25E-02 Grade 4 = ≥8 44 (46.3) 57 (42.5) 55 (41.4)
No uninvolved LN available for assessment NA 9 NA
Perivascular infiltrate SH Mets Replacement 48 NA NA
  Absent 28 (16.5) 22 (15.8)
 Mild (10-20%) 52 (30.6) 50 (35.9) Metastatic pattern
 Moderate (>20-<50%) 53 (31.2) 37 (26.6) Chi-square-test Subcapsular 4 (2.8) NA NA
 Strong (≥50%) 37 (21.8) 30 (21.6) 7.44E-01 Sinusoidal 7 (4.9) NA NA
Diffuse 6 (4.2) NA NA
Lymphocytic lobulitis Nodular 45 (31.5) NA NA
No normal breast lobules 39 (22.9) 25 (17.9) Mixed 61 (42.7) NA NA
  Absent 110 (83) 103 (90.4) Chi-square-test Total metastatic replacement of LN 20 (14) NA NA
 Present 21 (16) 11 (9.6) 1.88E-01
Tertiary lymphoid structures
  Absent 123 (72.4) 115 (82.7) Chi-square-test
 Present 47 (27.6) 24 (17.3) 4.32E-02
 LN-Positive Patients
Characteristics assessed
Table  1 
   Clinicopathological features All Breast Cancers 
N=309 (%) 
TNBC 
N=170 (%) 
 Age at diagnosis  
106 (34) 
 
61 (36) <Below 50 years 
Over 50 years 203 (66) 109 (64) 
 Tumor size, cm  
68 (22) 
 
35 (21) pT1 
pT2 183 (59) 103 (61) 
pT3 45 (15) 26 (15) 
Unknown 13 (4) 7 (4) 
 Histological grade  
9 (3) 
 
1 (0.5) I 
II 47 (15) 7 (4) 
III 253 (82) 162 (95.5) 
 Histological subtypes  
253 (81) 
 
143 (84) Invasive breast carcinoma of no special type 
Mixed ductal and lobular carcinoma 24 (8) 10 (5.8) 
Invasive lobular carcinoma 11 (4) 5 (2.9) 
Carcinoma with apocrine differentiation 9 (3) 2 (1.2) 
Metaplastic carcinoma of no special type 4 (1) 4 (2.4) 
Invasive papillary carcinoma 2 (0.6) 2 (1.2) 
Carcinoma with medullary features 2 (0.6) 2 (1.2) 
Salivary gland / skin adnexal type tumors 2 (0.6) 2 (1.2) 
Adenosquamous carcinoma 1 (0.3) 0 
Secretory carcinoma 1 (0.3) 0 
 DCIS  
143 (46) 
 
66 (39) Present 
Absent 163 (53) 102 (60) 
Unknown 3 (1) 2 (1) 
 Necrosis  
106 (34) 
 
61 (36) Present 
Absent 203 (66) 109 (64) 
 Fibrosis  
90 (29) 
 
54 (36) Present 
Absent 216 (70) 115 (64) 
Unknown 3 (1) 1 (0.5) 
 Lymphovascular invasion  
90 (29) 
 
45 (26) Present 
Absent 216 (70) 124 (73) 
Unknown 3 (1) 1 (0.5) 
 Lymph node status  
143 (46) 
 
64 (38) Positive 
Negative 133 (43) 81 (47) 
Unknown 33 (11) 25 (15) 
 Distant Metastasis  
129 (42) 
 
59 (35) Present 
Absent 180 (58) 111 (65) 
 Immunohistochemical subtypes  
62 (20) 
 
NA Hormone receptor+ /HER2- 
Hormone receptor-/HER2+ 59 (19) NA 
Hormone receptor+/HER2+ 18 (6) NA 
Triple Negative 170 (55) 170 (100) 
 EGFR  
67 (22) 
 
53 (31) Present 
Absent 225 (73) 106 (63) 
Unknown 17 (5) 11 (7) 
 CK5/6  
68 (22) 
 
57 (3) Present 
Absent 225 (73) 103 (61) 
Unknown 16 (5) 10 (6) 
 CK14  
49 (16) 
 
44 (26) Present 
Absent 244 (79) 114 (67) 
Unknown 16 (5) 12 (7) 
	
Table  3
Selected features to predict risk for 
developing distant metastasis
Group A Group B Group C Group A Group B Group C Group B Group B Group B Group B
Standard Immune & All Standard Immune & All Immune & Immune & Immune & Immune &
stroma features stroma features stroma stroma stroma stroma
LN-status 1.904 2.248 1.558 1.635
ER-status 0.7
HER2-status 1.797 1.76
LVI-status 1.483 1.642
Fibrosis 1.55
Salgado's classification 0.67 0.629 0.687 0.282
TILs at the invasive margin 0.509 0.571 0.487
Lmyphocytic lobulitis 0.368 0.436 0.591 0.339 0.196
Lymphoid infiltrate surrounding DCIS 0.358
Tertiary lymphoid structures 2.298 2.24
Oedematous/Myxoid stroma 1.889 2.22 3.32
Germinal centre, semi-quantitative 
assessment in uninvolved LN 0.348 0.248 0.413 0.451 0.212 0.11
Germinal centre, semi-quantitative 
assessment in involved LN 0.541 0.654 0.496 0.426
Germinal centre, size in uninvolved LN 2.216 2.071 2.659 2.713
Germinal centre, size in involved LN 3.504
Germinal centre, location in involved 
LN 2.932 3.04 3.401 3.758 2.234 2.898
Germinal centre, hyperplasia in 
uninvolved LN 1.59
Germinal centre, hyperplasia in 
involved LN 0.371 0.278 0.666
Metastatic pattern in involved LN 2.221 4.11 3.334
Feature selection from  multivariate Bayesian Cox regression analyses
LN-negativeLN-positive and LN-negative 
TNBCAll breast cancers All breast 
cancers
TNBC All breast 
cancers
TNBC
LN-positive
Supplementary Figure S1. Exemplars of stromal tissue stained with smooth muscle actin and Alcian blue.A. 
Oedematous/myxoid stroma with characteristically vacuolated material admixed with collagen fibres; B. fibroblastic stroma with 
numerous stromal cells (fibroblasts); C. hyalinised stroma. Figures show tissue stained with H&E; Smooth Muscle Actin (SMA) 
(Dako Ab Cat. #0851, antibody used at 1:200 concentration, antigen retrieval performed with 18min microwaving in citric buffer 
pH6.); and Alcian blue staining (Alcian blue 8GX, Generon).  
 
 
 
 
Quantification of SMA with HistoQuest. A. oedematous/myxoid stroma; B. fibroblastic stroma; C. hyalinised stroma. 
 
	
	
Histograms of DAB stained 
surface areas in µm2. 
Supplementary Figure S2 
 
I A. Lymph node with predominantly primary follicles (H&E); B. Lymph node with predominantly primary 
follicles (CD20); C. Lymph node with secondary follicles with germinal centres and sinus histiocytosis 
(H&E); D. Lymph node with secondary follicles with germinal centres (CD20).  
 
 
 
 
II A. Primary follicles; B. Germinal centre; Tissue stained with a B cell marker CD20 [Dako Cat. #7019, 
citrate buffer, 1:50 dilution] and a dendritic cell marker CD11c [Abcam Cat. #52631, citrate buffer, 1:100 
dilution]. 
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Supplementary Figure S3: Identification of overfitting point in the Bayesian batch Cox 
analysis. Graphs illustrating the fraction of correctly predicted disease outcome for patients 
(i.e. those who had an event prior the cut-off time) (prediction time point) over those patients 
who had either never distant metastasis or developed metastasis after this time point. The top 
and bottom lines represent the validation and test sets, respectively. The number of covariates 
used for the prediction is shown on the x-axis (nr of covs). Iteratively, covariates are removed 
from the analysis. 
 
 
 
 
 
